Zasocitinib

TAK-279
Identifiers
	IUPAC name N-[(1R,2R)-2-methoxycyclobutyl]-7-(methylamino)-5-[(2-oxo-1-pyridin-2-ylpyridin-3-yl)amino]pyrazolo[1,5-a]pyrimidine-3-carboxamide;
CAS Number	2272904-53-5;
PubChem CID	137441492;
ChemSpider	115277123;
UNII	C293MNS6TQ;
ChEMBL	ChEMBL5314423;
Chemical and physical data
Formula	C23H24N8O3
Molar mass	460.498 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CNC1=CC(=NC2=C(C=NN12)C(=O)N[C@@H]3CC[C@H]3OC)NC4=CC=CN(C4=O)C5=CC=CC=N5;
	InChI InChI=1S/C23H24N8O3/c1-24-20-12-18(27-16-6-5-11-30(23(16)33)19-7-3-4-10-25-19)29-21-14(13-26-31(20)21)22(32)28-15-8-9-17(15)34-2/h3-7,10-13,15,17,24H,8-9H2,1-2H3,(H,27,29)(H,28,32)/t15-,17-/m1/s1; Key:BWINBHTTZLVXGT-NVXWUHKLSA-N;

Zasocitinib (TAK-279, NDI-034858) is a drug which is an orally active, highly selective tyrosine kinase 2 (TYK2) inhibitor. It has been researched for various inflammatory conditions including psoriatic arthritis and Crohn's disease.^[1]^[2]^[3] It is significantly more selective than earlier compounds over side targets such as JAK1, which is hoped to give it an improved side effect profile.^[4]

References[edit]

^ Leit S, Greenwood J, Carriero S, Mondal S, Abel R, Ashwell M, et al. (August 2023). "Discovery of a Potent and Selective Tyrosine Kinase 2 Inhibitor: TAK-279". Journal of Medicinal Chemistry. 66 (15): 10473–10496. doi:10.1021/acs.jmedchem.3c00600. PMID 37427891.
^ Kivitz AJ (14 November 2023). "The investigational tyrosine kinase inhibitor TAK-279 is effective and well tolerated in patients with active psoriatic arthritis in phase 2b study". Cleveland Clinic Journal of Medicine.
^ Kivitz A, Muensterman ET, Kavanaugh A, Van der Heijde D, Klimiuk PA, Valenzuela G, et al. (24 October 2023). "Efficacy and Safety Outcomes of TAK-279, a Selective Oral Tyrosine Kinase 2 (TYK2) Inhibitor, from a Randomized, Double-blind, Placebo-controlled Phase 2b Trial in Patients with Active Psoriatic Arthritis". American College of Rheumatology.
^ "The Discovery Process of TAK-279 and the Deep Logic Behind its Acquisition by Takeda". synapse.patsnap.com. 10 August 2023.

This pharmacology-related article is a stub. You can help Wikipedia by expanding it.

[pmid37427891-1] Leit S, Greenwood J, Carriero S, Mondal S, Abel R, Ashwell M, et al. (August 2023). "Discovery of a Potent and Selective Tyrosine Kinase 2 Inhibitor: TAK-279". Journal of Medicinal Chemistry. 66 (15): 10473–10496. doi:10.1021/acs.jmedchem.3c00600. PMID 37427891.

[2] Kivitz AJ (14 November 2023). "The investigational tyrosine kinase inhibitor TAK-279 is effective and well tolerated in patients with active psoriatic arthritis in phase 2b study". Cleveland Clinic Journal of Medicine.

[3] Kivitz A, Muensterman ET, Kavanaugh A, Van der Heijde D, Klimiuk PA, Valenzuela G, et al. (24 October 2023). "Efficacy and Safety Outcomes of TAK-279, a Selective Oral Tyrosine Kinase 2 (TYK2) Inhibitor, from a Randomized, Double-blind, Placebo-controlled Phase 2b Trial in Patients with Active Psoriatic Arthritis". American College of Rheumatology.

[4] "The Discovery Process of TAK-279 and the Deep Logic Behind its Acquisition by Takeda". synapse.patsnap.com. 10 August 2023.

[1]

[2]

[3]

[4]

See also[edit]

References[edit]